Victoria's minister for innovation and medical research, Jaala Pulford said that "this agreement with one of the world’s leading biopharmaceutical companies is a strong endorsement of the strength of Victoria’s research and development community and recognises our status as one of the world leaders in this field."
According to the Victorian government, experts from Pfizer’s Centers for Therapeutic Innovation (CTI) and RNA Accelerator will be working with mRNA Victoria—a government-funded mRNA organisation—to advance critical skills and connections with Victorian researchers and industry.
“This initiative between mRNA Victoria and Pfizer will also deliver significant job opportunities for our state as leading biotech research and commercialisation is ramped up,” Pulford said on March 18.
Established in 2010, Pfizer’s CTI is a joint drug discovery model focused on collaborating globally with academic institutions to translate scientific research into treatment products.
No information has currently been revealed on Pfizer’s RNA Accelerator, but the Victorian Government said that the Accelerator builds on the success of the CTI model for “external innovation and expand the company’s leadership in RNA therapeutics.”
The vaccine is currently going through its Phase 1 clinical trials with preliminary results expected to be made available in the first half of 2022.
The trials were due to start in late 2021 or January 2022 and serve as a collaboration between the Monash Institute of Pharmaceutical Sciences and the Doherty Institute, both from Victoria’s leading universities.
The Andrews Government said that the first initiative between the state and Pfizer will be a conference “to present high-impact Australian mRNA and RNA research, paving the way for greater collaborations with Pfizer’s CTI and RNA Accelerator.”
The new announcement was made during the self-quarantine period for Foley.